{"id":"bergapten","rwe":[],"tags":[{"label":"bergapten","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Cytochrome P450 1A1","category":"target"},{"label":"CYP1A1","category":"gene"},{"label":"TAS2R10","category":"gene"},{"label":"MAOA","category":"gene"},{"label":"D05BA03","category":"atc"},{"label":"Active","category":"status"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Dermatologic Agents","category":"pharmacology"},{"label":"Photosensitizing Agents","category":"pharmacology"},{"label":"Radiation-Sensitizing Agents","category":"pharmacology"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"heraclin","offLabel":[],"synonyms":["bergapten","5-Methoxy-6,7-furanocoumarin","5-Methoxypsoralen","bergaptan","bergaptene","heraclin"],"timeline":[],"aiSummary":"Heraclin, also known as Bergapten, is a small molecule drug that targets Cytochrome P450 1A1. It belongs to the bergapten drug class, but its commercial status and approved indications are unknown. The mechanism of action and pharmacokinetic properties of Heraclin are also not well-documented. As a result, it is difficult to provide a comprehensive summary of this compound. Further research is needed to understand its potential therapeutic applications and safety profile.","brandName":"Heraclin","ecosystem":[],"mechanism":{"target":"Taste receptor type 2 member 10, Cytochrome P450 1A1, Amine oxidase [flavin-containing] A","targets":[{"gene":"CYP1A1","source":"DrugCentral","target":"Cytochrome P450 1A1","protein":"Cytochrome P450 1A1"},{"gene":"TAS2R10","source":"DrugCentral","target":"Taste receptor type 2 member 10","protein":"Taste receptor type 2 member 10"},{"gene":"MAOA","source":"DrugCentral","target":"Amine oxidase [flavin-containing] A","protein":"Amine oxidase [flavin-containing] A"}],"modality":"Small Molecule","drugClass":"bergapten","explanation":"Think of Heraclin like a traffic cop that helps control the flow of chemicals in your body. By blocking the enzyme Cytochrome P450 1A1, Heraclin can affect how your body processes certain substances, which may help treat certain conditions. However, more research is needed to understand how this works and what effects it may have on the body.","oneSentence":"Heraclin works by inhibiting the enzyme Cytochrome P450 1A1, which plays a role in the metabolism of various substances in the body.","technicalDetail":"Heraclin exerts its effects by competitively inhibiting the activity of Cytochrome P450 1A1, a member of the cytochrome P450 enzyme family involved in the metabolism of various endogenous and exogenous compounds."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3021","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=BERGAPTEN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BERGAPTEN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:56:29.095436","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:43:03.960731+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"trioxsalen","drugSlug":"trioxsalen","fdaApproval":"1964-07-24","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"methoxsalen","drugSlug":"methoxsalen","fdaApproval":"1954-12-03","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"bergapten","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"trioxsalen","brandName":"trioxsalen","genericName":"trioxsalen","approvalYear":"1964","relationship":"same-class"},{"drugId":"methoxsalen","brandName":"methoxsalen","genericName":"methoxsalen","approvalYear":"1954","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00811005","phase":"PHASE3","title":"Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2008-10","conditions":["Pustular Palmoplantar Psoriasis"],"enrollment":20,"completionDate":"2010-10"},{"nctId":"NCT00533195","phase":"PHASE3","title":"Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2007-10","conditions":["Atopic Dermatitis"],"enrollment":20,"completionDate":"2009-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"005216","UNII":"4FVK84C92X","CHEBI":"CHEBI:18293","RXNORM":"15842","UMLSCUI":"C0049289","ChEMBL_ID":"CHEMBL24171","KEGG_DRUG":"D07521","DRUGBANK_ID":"DB12216","PUBCHEM_CID":"2355","SNOMEDCT_US":"429146002","IUPHAR_LIGAND_ID":"12431","MESH_DESCRIPTOR_UI":"D000078223"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":551,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"D05BA03","allCodes":["D05BA03"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:43:03.960731+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}